TY - STD TI - Global tuberculosis report. 2015. http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf. Accessed 1 June 2016. UR - http://apps.who.int/iris/bitstream/10665/191102/1/9789241565059_eng.pdf ID - ref1 ER - TY - STD TI - Qatar-Wikipedia. https://en.wikipedia.org/wiki/Qatar. Accessed 5 Dec 2016 UR - https://en.wikipedia.org/wiki/Qatar ID - ref2 ER - TY - BOOK AU - Belair, F. D. E. PY - 2014 DA - 2014// TI - Demography, migration and labour market in Qatar-Cadmus Home ID - Belair2014 ER - TY - STD TI - Abou Khattab M, Khan F, Al Maslamani M, Al- Khal AL, El Gendy A, Al Soub H, Howady FS. Pulmonary and Extra Pulmonary Tuberculosis in Qatar: A First Retrospective Population-Based Study. Adv Infect Dis. 2015;5:148–53. ID - ref4 ER - TY - BOOK PY - 2014 DA - 2014// TI - Tuberculosis Country Profiles ID - ref5 ER - TY - JOUR AU - Monedero, I. AU - Caminero, J. A. PY - 2011 DA - 2011// TI - Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review JO - Int J Tuberc Lung Dis VL - 15 UR - https://doi.org/10.5588/ijtld.09.0439 DO - 10.5588/ijtld.09.0439 ID - Monedero2011 ER - TY - JOUR AU - Blomberg, B. AU - Fourie, B. PY - 2003 DA - 2003// TI - Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens JO - Drugs VL - 63 UR - https://doi.org/10.2165/00003495-200363060-00002 DO - 10.2165/00003495-200363060-00002 ID - Blomberg2003 ER - TY - JOUR AU - Chaulet, P. PY - 1999 DA - 1999// TI - Implementation of fixed-dose combinations in tuberculosis control: outline of responsibilities JO - Int J Tuberc Lung Dis VL - 3 ID - Chaulet1999 ER - TY - JOUR AU - Blomberg, B. AU - Spinaci, S. AU - Fourie, B. AU - Laing, R. PY - 2001 DA - 2001// TI - The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis JO - Bull World Health Organ VL - 79 ID - Blomberg2001 ER - TY - JOUR AU - Pillai, G. AU - Fourie, P. B. AU - Padayatchi, N. AU - Onyebujoh, P. C. AU - McIlleron, H. AU - Smith, P. J. AU - Gabriels, G. PY - 1999 DA - 1999// TI - Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market JO - Int J Tuberc Lung Dis VL - 3 ID - Pillai1999 ER - TY - JOUR AU - Laserson, K. F. AU - Kenyon, A. S. AU - Kenyon, T. A. AU - Layloff, T. AU - Binkin, N. J. PY - 2001 DA - 2001// TI - Substandard tuberculosis drugs on the global market and their simple detection JO - Int J Tuberc Lung Dis VL - 5 ID - Laserson2001 ER - TY - JOUR AU - Agrawal, S. AU - Singh, I. AU - Kaur, K. J. AU - Bhade, S. R. AU - Kaul, C. L. AU - Panchagnula, R. PY - 2004 DA - 2004// TI - Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels JO - Int J Pharm VL - 276 UR - https://doi.org/10.1016/j.ijpharm.2004.02.019 DO - 10.1016/j.ijpharm.2004.02.019 ID - Agrawal2004 ER - TY - JOUR AU - Panchagnula, R. AU - Agrawal, S. AU - Kaur, K. J. AU - Singh, I. AU - Kaul, C. L. PY - 2000 DA - 2000// TI - Evaluation of rifampicin bioequivalence in fixed-dose combinations using the WHO/IUATLD recommended protocol JO - Int J Tuberc Lung Dis VL - 4 ID - Panchagnula2000 ER - TY - JOUR AU - Agrawal, S. AU - Kaur, K. J. AU - Singh, I. AU - Bhade, S. R. AU - Kaul, C. L. AU - Panchagnula, R. PY - 2002 DA - 2002// TI - Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels JO - Int J Pharm VL - 233 UR - https://doi.org/10.1016/S0378-5173(01)00939-5 DO - 10.1016/S0378-5173(01)00939-5 ID - Agrawal2002 ER - TY - JOUR AU - Bhutani, H. AU - Mariappan, T. T. AU - Singh, S. PY - 2004 DA - 2004// TI - The physical and chemical stability of anti-tuberculosis fi xed-dose combination products under accelerated climatic conditions JO - Int J Tuberc Lung Dis VL - 8 ID - Bhutani2004 ER - TY - JOUR AU - Ashokraj, Y. AU - Kohli, G. AU - Kaul, C. L. AU - Panchagnula, R. PY - 2005 DA - 2005// TI - Quality control of anti-tuberculosis FDC formulations in the global market: Part II. Accelerated stability studies JO - Int J Tuberc Lung Dis VL - 9 ID - Ashokraj2005 ER - TY - JOUR AU - Gabriels, G. A. AU - McIlleron, H. AU - Smith, P. J. AU - Folb, P. I. AU - Fourie, P. B. PY - 2007 DA - 2007// TI - Modification to improve efficiency of sampling schedules for BA/BE testing of FDC anti-tuberculosis drugs JO - Int J Tuberc Lung Dis VL - 11 ID - Gabriels2007 ER - TY - BOOK PY - 2014 DA - 2014// TI - Mycobacteriology laboratory manual PB - Global Laboratory Initiative, World Health Organization CY - Geneva ID - ref18 ER - TY - JOUR AU - Bartacek, A. AU - Schütt, D. AU - Panosch, B. AU - Borek, M. PY - 2009 DA - 2009// TI - Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis JO - Int J Tuberc Lung Dis VL - 13 ID - Bartacek2009 ER - TY - JOUR AU - Wu, J. T. AU - Chiu, C. T. AU - Wei, Y. F. AU - Lai, Y. F. PY - 2015 DA - 2015// TI - Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment JO - Clinics VL - 70 UR - https://doi.org/10.6061/clinics/2015(06)08 DO - 10.6061/clinics/2015(06)08 ID - Wu2015 ER - TY - JOUR AU - Liendhardt, C. AU - Cook, S. V. AU - Burgos, M. AU - Yorke-Edwards, V. AU - Rigouts, L. AU - Anyo, G. AU - Kim, S. J. AU - Jindani, A. AU - Enarson, D. A. AU - Nunn, A. J. PY - 2011 DA - 2011// TI - Efficacy and Safety of a 4-Drug Fixed-Dose Combination Regimen Compared With Separate Drugs for Treatment of Pulmonary Tuberculosis. The Study C Randomized Controlled Trial JO - JAMA VL - 305:14 UR - https://doi.org/10.1001/jama.2011.436 DO - 10.1001/jama.2011.436 ID - Liendhardt2011 ER - TY - JOUR AU - Albanna, A. AU - Smith, B. AU - Cowan, D. AU - Menzies, D. PY - 2013 DA - 2013// TI - Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis JO - Eur Respir J VL - 42 UR - https://doi.org/10.1183/09031936.00180612 DO - 10.1183/09031936.00180612 ID - Albanna2013 ER - TY - STD TI - Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, Roqué i Figuls M, Parker LA, Caylà J, Bonfill Cosp X. Fixed-dose combinations for treating pulmonary tuberculosis. Cohrane Database Sys Rev. 2016;17(5):1–142. ID - ref23 ER - TY - STD TI - Griffith D, Brown-Elliot B, Shepherd S, Mclarty J, Griffith L, Wallace R. Ethambutol Ocular Toxicity in Treatment Regimens for Mycobacterium avium Complex Lung Disease. AJRCCM. 2005;172(2):250–253. ID - ref24 ER - TY - JOUR AU - Alisjahbana, B. AU - Sahiratmadja, E. AU - Nelwan, E. J. AU - Purwa, A. M. AU - Ahmad, Y. AU - Ottenhoff, T. H. AU - Nelwan, R. H. AU - Parwati, I. AU - Meer, J. W. AU - Crevel, R. PY - 2007 DA - 2007// TI - The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis JO - Clin Infect Dis VL - 45 UR - https://doi.org/10.1086/519841 DO - 10.1086/519841 ID - Alisjahbana2007 ER - TY - JOUR AU - Viswanathan, A. A. AU - Gawde, N. C. PY - 2014 DA - 2014// TI - Effect of type II diabetes mellitus on treatment outcomes of tuberculosis JO - Lung India VL - 31 UR - https://doi.org/10.4103/0970-2113.135764 DO - 10.4103/0970-2113.135764 ID - Viswanathan2014 ER - TY - JOUR AU - Hongguang, C. AU - Min, L. AU - Shiwen, J. AU - Fanghui, G. AU - Shaoping, H. AU - Tiejie, G. AU - Na, L. AU - Zhiguo, Z. PY - 2015 DA - 2015// TI - Impact of diabetes on clinical presentation and treatment outcome of pulmonary tuberculosis in Beijing JO - Epidemiol Infect VL - 143 UR - https://doi.org/10.1017/S095026881400079X DO - 10.1017/S095026881400079X ID - Hongguang2015 ER - TY - JOUR AU - Dooley, K. E. AU - Chaisson, R. E. PY - 2009 DA - 2009// TI - Tuberculosis and diabetes mellitus: convergence of two epidemics JO - Lancet Infect Dis VL - 9 UR - https://doi.org/10.1016/S1473-3099(09)70282-8 DO - 10.1016/S1473-3099(09)70282-8 ID - Dooley2009 ER - TY - JOUR AU - Nijland, H. M. AU - Ruslami, R. AU - Stalenhoef, J. E. AU - Nelwan, E. J. AU - Alisjahbana, B. AU - Nelwan, R. H. AU - Ven, A. J. AU - Danusantoso, H. AU - Aarnoutse, R. E. AU - Crevel, R. PY - 2006 DA - 2006// TI - Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes JO - Clin Infect Dis VL - 43 UR - https://doi.org/10.1086/507543 DO - 10.1086/507543 ID - Nijland2006 ER - TY - JOUR AU - Heysell, S. K. AU - Moore, J. L. AU - Staley, D. AU - Dodge, D. AU - Houpt, E. R. PY - 2013 DA - 2013// TI - Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA JO - Tuberc Res Treat VL - 2013 ID - Heysell2013 ER - TY - JOUR AU - Heysell, S. K. AU - Moore, J. L. AU - Keller, S. J. AU - Houpt, E. R. PY - 2010 DA - 2010// TI - Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA JO - Emerg Infect Dis VL - 16 UR - https://doi.org/10.3201/eid1610.100374 DO - 10.3201/eid1610.100374 ID - Heysell2010 ER - TY - JOUR AU - Ruslami, R. AU - Nijland, H. M. AU - Adhiarta, I. G. AU - Kariadi, S. H. AU - Alisjahbana, B. AU - Aarnoutse, R. E. AU - Crevel, R. PY - 2010 DA - 2010// TI - Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes JO - Antimicrob Agents Chemother VL - 54 UR - https://doi.org/10.1128/AAC.00447-09 DO - 10.1128/AAC.00447-09 ID - Ruslami2010 ER -